ArticleAmerican journal of translational research2018
FOXD1 predicts prognosis of colorectal cancer patients and promotes colorectal cancer progression via the ERK 1/2 pathway.
Article in American journal of translational research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Expression and Survival Significance of FOXD1 in Lung Squamous Cell Carcinoma: A Meta-Analysis, Immunohistochemistry Validation, and Bioinformatics Analysis.BioMed research international · 2022Pooled it
- The Senescence-SASP Landscape in Colon Adenocarcinoma: Prognostic and Therapeutic Implications.Current issues in molecular biology · 2026Article
- Neural crest-associated gene FOXD1 induces an immunosuppressive microenvironment by regulating myeloid-derived suppressor cells in melanoma.Journal for immunotherapy of cancer · 2025Article
- Integrated singlecell and bulk RNA-seq analysis identifies a prognostic signature related to inflammation in colorectal cancer.Scientific reports · 2025Article
- Enhancing fibroblast-epithelial cell communications: Serpine2 as a key molecule inFrontiers in immunology · 2025Article
- Wnt/β-catenin signaling regulates amino acid metabolism through the suppression of CEBPA and FOXA1 in liver cancer cells.Communications biology · 2024Article
- Forkhead box D subfamily genes in colorectal cancer: potential biomarkers and therapeutic targets.PeerJ · 2024Article
- Prognostic and clinicopathological significance of FOXD1 in various cancers: a meta and bioinformation analysis.Future science OA · 2024Review
- Dysregulated Forkhead Box (FOX) Genes Association with Survival Prognosis, Anti-tumor Immunity, and Key Targeting Drugs in Colon Adenocarcinoma.Archives of Iranian medicine · 2023Article
- FOXD1 promotes chemotherapy resistance by enhancing cell stemness in colorectal cancer through β‑catenin nuclear localization.Oncology reports · 2023Article
- Identifying the tumor location-associated candidate genes in development of new drugs for colorectal cancer using machine-learning-based approach.Medical & biological engineering & computing · 2022Article
- Combination of FOXD1 and Plk2: A novel biomarker for predicting unfavourable prognosis of colorectal cancer.Journal of cellular and molecular medicine · 2022Article
- Bioinformatics analysis reveals immune prognostic markers for overall survival of colorectal cancer patients: a novel machine learning survival predictive system.BMC bioinformatics · 2022Article
- E2F transcription factor 1/small nucleolar RNA host gene 18/microRNA-338-5p/forkhead box D1: an important regulatory axis in glioma progression.Bioengineered · 2022Article
- Aberrant overexpression of transcription factor Forkhead box D1 predicts poor prognosis and promotes cancer progression in HNSCC.BMC cancer · 2021Article
- FOXD1 is a prognostic biomarker and correlated with macrophages infiltration in head and neck squamous cell carcinoma.Bioscience reports · 2021Article
- FOXD1 regulates cell division in clear cell renal cell carcinoma.BMC cancer · 2021Article
- Diagnostic and prognostic value ofJournal of Cancer · 2021Article
- Article
- LncRNA OIP5-AS1 promotes the malignancy of pancreatic ductal adenocarcinoma via regulating miR-429/FOXD1/ERK pathway.Cancer cell international · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies indicated a critical role of foxhead box D1 (FOXD1) in human cancers. However, its expression pattern in colorectal cancer (CRC) and the molecular mechanism of FOXD1 on cancer progression remain unknown. In this study, we found that FOXD1 was aberrantly overexpressed in human CRC tissues, and FOXD1 levels were correlated with tumor size, differentiation, TNM stage and lymph node metastasis and poor prognosis. Knockdown of FOXD1 attenuated CRC cell proliferation, migration and invasion. Overexpression of FOXD1 produced the opposite effects. These effects were mediated by activation of the ERK 1/2 signaling pathway, and inhibition of this pathway with a specific ERK 1/2 inhibitor (U0126) could impair the tumor-promoting effects induced by overexpression of FOXD1. Taken together, these findings indicate that FOXD1 promotes tumorgenesis and progression of CRC by activating ERK 1/2 signaling pathway and may represent a potential clinical target.
Indexed as
Identifiers
29887965PMC5992558What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.